Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape

Valentina Grossi, Candida Fasano, Valentina Celestini, Martina Lepore Signorile, Paola Sanese, Cristiano Simone

Research output: Contribution to journalReview article

Abstract

Colorectal cancer (CRC) poses a formidable challenge in terms of molecular heterogeneity, as it involves a variety of cancer-related pathways and molecular changes unique to an individual's tumor. On the other hand, recent advances in DNA sequencing technologies provide an unprecedented capacity to comprehensively identify the genetic alterations resulting in tumorigenesis, raising the hope that new therapeutic approaches based on molecularly targeted drugs may prevent the occurrence of chemoresistance. Regulation of the transcription factor FOXO3a in response to extracellular cues plays a fundamental role in cellular homeostasis, being part of the molecular machinery that drives cells towards survival or death. Indeed, FOXO3a is controlled by a range of external stimuli, which not only influence its transcriptional activity, but also affect its subcellular localization. These regulation mechanisms are mediated by cancer-related signaling pathways that eventually drive changes in FOXO3a post-translational modifications (e.g., phosphorylation). Recent results showed that FOXO3a is imported into the mitochondria in tumor cells and tissues subjected to metabolic stress and cancer therapeutics, where it induces expression of the mitochondrial genome to support mitochondrial metabolism and cell survival. The current review discusses the potential clinical relevance of multidrug therapies that drive cancer cell fate by regulating critical pathways converging on FOXO3a.

Original languageEnglish
JournalCancers
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 23 2019

Fingerprint

Colorectal Neoplasms
Neoplasms
Cell Survival
Hope
Physiological Stress
Critical Pathways
Mitochondrial Genome
Post Translational Protein Processing
DNA Sequence Analysis
Cues
Mitochondria
Carcinogenesis
Homeostasis
Cell Death
Transcription Factors
Therapeutics
Phosphorylation
Technology
Pharmaceutical Preparations
Drive

Cite this

Chasing the FOXO3 : Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. / Grossi, Valentina; Fasano, Candida; Celestini, Valentina; Lepore Signorile, Martina; Sanese, Paola; Simone, Cristiano.

In: Cancers, Vol. 11, No. 3, 23.03.2019.

Research output: Contribution to journalReview article

Grossi, Valentina ; Fasano, Candida ; Celestini, Valentina ; Lepore Signorile, Martina ; Sanese, Paola ; Simone, Cristiano. / Chasing the FOXO3 : Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape. In: Cancers. 2019 ; Vol. 11, No. 3.
@article{bd011fc2f997480798639cb72a2f3f51,
title = "Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape",
abstract = "Colorectal cancer (CRC) poses a formidable challenge in terms of molecular heterogeneity, as it involves a variety of cancer-related pathways and molecular changes unique to an individual's tumor. On the other hand, recent advances in DNA sequencing technologies provide an unprecedented capacity to comprehensively identify the genetic alterations resulting in tumorigenesis, raising the hope that new therapeutic approaches based on molecularly targeted drugs may prevent the occurrence of chemoresistance. Regulation of the transcription factor FOXO3a in response to extracellular cues plays a fundamental role in cellular homeostasis, being part of the molecular machinery that drives cells towards survival or death. Indeed, FOXO3a is controlled by a range of external stimuli, which not only influence its transcriptional activity, but also affect its subcellular localization. These regulation mechanisms are mediated by cancer-related signaling pathways that eventually drive changes in FOXO3a post-translational modifications (e.g., phosphorylation). Recent results showed that FOXO3a is imported into the mitochondria in tumor cells and tissues subjected to metabolic stress and cancer therapeutics, where it induces expression of the mitochondrial genome to support mitochondrial metabolism and cell survival. The current review discusses the potential clinical relevance of multidrug therapies that drive cancer cell fate by regulating critical pathways converging on FOXO3a.",
author = "Valentina Grossi and Candida Fasano and Valentina Celestini and {Lepore Signorile}, Martina and Paola Sanese and Cristiano Simone",
year = "2019",
month = "3",
day = "23",
doi = "10.3390/cancers11030414",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "3",

}

TY - JOUR

T1 - Chasing the FOXO3

T2 - Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape

AU - Grossi, Valentina

AU - Fasano, Candida

AU - Celestini, Valentina

AU - Lepore Signorile, Martina

AU - Sanese, Paola

AU - Simone, Cristiano

PY - 2019/3/23

Y1 - 2019/3/23

N2 - Colorectal cancer (CRC) poses a formidable challenge in terms of molecular heterogeneity, as it involves a variety of cancer-related pathways and molecular changes unique to an individual's tumor. On the other hand, recent advances in DNA sequencing technologies provide an unprecedented capacity to comprehensively identify the genetic alterations resulting in tumorigenesis, raising the hope that new therapeutic approaches based on molecularly targeted drugs may prevent the occurrence of chemoresistance. Regulation of the transcription factor FOXO3a in response to extracellular cues plays a fundamental role in cellular homeostasis, being part of the molecular machinery that drives cells towards survival or death. Indeed, FOXO3a is controlled by a range of external stimuli, which not only influence its transcriptional activity, but also affect its subcellular localization. These regulation mechanisms are mediated by cancer-related signaling pathways that eventually drive changes in FOXO3a post-translational modifications (e.g., phosphorylation). Recent results showed that FOXO3a is imported into the mitochondria in tumor cells and tissues subjected to metabolic stress and cancer therapeutics, where it induces expression of the mitochondrial genome to support mitochondrial metabolism and cell survival. The current review discusses the potential clinical relevance of multidrug therapies that drive cancer cell fate by regulating critical pathways converging on FOXO3a.

AB - Colorectal cancer (CRC) poses a formidable challenge in terms of molecular heterogeneity, as it involves a variety of cancer-related pathways and molecular changes unique to an individual's tumor. On the other hand, recent advances in DNA sequencing technologies provide an unprecedented capacity to comprehensively identify the genetic alterations resulting in tumorigenesis, raising the hope that new therapeutic approaches based on molecularly targeted drugs may prevent the occurrence of chemoresistance. Regulation of the transcription factor FOXO3a in response to extracellular cues plays a fundamental role in cellular homeostasis, being part of the molecular machinery that drives cells towards survival or death. Indeed, FOXO3a is controlled by a range of external stimuli, which not only influence its transcriptional activity, but also affect its subcellular localization. These regulation mechanisms are mediated by cancer-related signaling pathways that eventually drive changes in FOXO3a post-translational modifications (e.g., phosphorylation). Recent results showed that FOXO3a is imported into the mitochondria in tumor cells and tissues subjected to metabolic stress and cancer therapeutics, where it induces expression of the mitochondrial genome to support mitochondrial metabolism and cell survival. The current review discusses the potential clinical relevance of multidrug therapies that drive cancer cell fate by regulating critical pathways converging on FOXO3a.

U2 - 10.3390/cancers11030414

DO - 10.3390/cancers11030414

M3 - Review article

C2 - 30909600

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

ER -